Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antibiotic Development: FDA Says New Guidances Will Help, But Industry Questions Statistical Focus

Executive Summary

Industry is questioning the fundamental statistical underpinnings of FDA's approval pathways for antibiotics even as the agency prepares to roll out several guidances to help clarify them

You may also be interested in...



FDA Raises Breakpoints In Final Labeling For Forest's Ceftaroline

FDA demonstrated a willingness to be flexible about antibiotic breakpoints in its Oct. 29 approval of Forest Laboratories' ceftaroline fosamil.

FDA Raises Breakpoints In Final Labeling For Forest's Ceftaroline

FDA demonstrated a willingness to be flexible about antibiotic breakpoints in its Oct. 29 approval of Forest Laboratories' ceftaroline fosamil.

User Fee Discussions Include Funding Parts Of FDA Regulatory Science Plan

Commissioner Margaret Hamburg’s plans to improve regulatory science at FDA could benefit from application user fees, based on PDUFA negotiations.

Related Content

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel